Market Place
Sourcing Support
Innovent Biologics Unveils "Dual Innovations" at Oncology R&D Day
30 Jun 2025 //
PR NEWSWIRE
Lilly, Innovent`s Mazdutide Nabs First-In-Class Nod in China
28 Jun 2025 //
FIERCE PHARMA
Mazdutide Approved in China for Chronic Weight Management
27 Jun 2025 //
PR NEWSWIRE
Innovent presents Mazdutide Phase 3 study at ADA 85th Sessions
24 Jun 2025 //
PR NEWSWIRE
Innovent to Showcase Research Results at ADA 85th Sessions
22 Jun 2025 //
PR NEWSWIRE
Innovent Begins 7th Ph3 Trial of Mazdutide in China
15 Jun 2025 //
PR NEWSWIRE
Innovent to Present R&D Results at ADA`s 85th Scientific Sessions
12 Jun 2025 //
PR NEWSWIRE
Hutchmed, Innovent File NDA in China for Renal Cell Carcinoma
06 Jun 2025 //
GLOBENEWSWIRE
Innovent`s IBI363 gets 2nd NMPA Breakthrough for Lung Cancer
04 Jun 2025 //
PR NEWSWIRE
Innovent Presents Ph 1 IBI363 Lung Cancer Data at ASCO
03 Jun 2025 //
PR NEWSWIRE
Innovent Presents IBI354 Ph1/2 Data In HER2 Solid Tumors At ASCO
02 Jun 2025 //
PR NEWSWIRE
Innovent Presents IBI343 Ph1 Data In Pancreatic Cancer At ASCO
02 Jun 2025 //
PR NEWSWIRE
Innovent Biologics Updates IBI363 Phase 1 Study at ASCO
01 Jun 2025 //
PR NEWSWIRE
ASCO 2025: Innovent Biologics Updates Data on IBI363 in Melanoma
31 May 2025 //
PR NEWSWIRE
Innovent Doses First Patient In Ph3 Picankibart Psoriasis Study
28 May 2025 //
PR NEWSWIRE
Ph 3 Mazdutide Obesity Study Published in NEJM
25 May 2025 //
PR NEWSWIRE
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable
19 May 2025 //
PR NEWSWIRE
Innovent`s 2024 ESG Report Highlights Sustainable Commitment
18 May 2025 //
PR NEWSWIRE
GLORY-3: Second Phase 3 Study of Mazdutide vs Semaglutide Begins
15 May 2025 //
PR NEWSWIRE
Innovent starts Ph 2 study of Efdamrofusp for Diabetic Macular Edema
06 May 2025 //
PR NEWSWIRE
Innovent Presents Phase 2 data for Efdamrofusp Alfa at ARVO 2025
05 May 2025 //
PR NEWSWIRE
Innovent Doses First Patient in Phase 1 Study of IBI3020 ADC
29 Apr 2025 //
PR NEWSWIRE
Innovent Presents Preclinical Data of Multiple Novel Molecules
27 Apr 2025 //
PR NEWSWIRE
Innovent`s Limertinib Approved by NMPA for Lung Cancer Treatment
25 Apr 2025 //
PR NEWSWIRE
Innovent to Present Breakthrough Data of IBI363 at 2025 ASCO Meeting
23 Apr 2025 //
PR NEWSWIRE
Innovent`s Sycume to transform thyroid eye disease treatment
18 Apr 2025 //
EXPRESSPHARMA
Innovent`s IBI363 Granted NMPA Breakthrough Therapy for Melanoma
30 Mar 2025 //
PR NEWSWIRE
Innovent Announces 2024 Annual Results and Business Updates
26 Mar 2025 //
PR NEWSWIRE
Innovent to Present Novel Molecules at 2025 AACR Annual Meeting
26 Mar 2025 //
PR NEWSWIRE
Innovent Doses First Patient In Ph 3 IBI354 Clinical Study
23 Mar 2025 //
PR NEWSWIRE
Innovent and HUTCHMED announce FRUSICA-2 study results
18 Mar 2025 //
PR NEWSWIRE
HUTCHMED and Innovent announce FRUSICA-2 study success in China
18 Mar 2025 //
GLOBENEWSWIRE
Innovent`s SYCUME® Approved by NMPA for Thyroid Eye Disease
14 Mar 2025 //
PR NEWSWIRE
Innovent Doses First Patient in IBI363 Melanoma Pivotal Study
03 Mar 2025 //
PR NEWSWIRE
NMPA Grants Review To Innovent’s Ipilimumab Combo In Colon Cancer
23 Feb 2025 //
PR NEWSWIRE
Innovent Gets Second FDA Fast Track For IBI363 In NSCLC
17 Feb 2025 //
PR NEWSWIRE
Innovent Gets Second Fast Track Nod For IBI363 In NSCLC
16 Feb 2025 //
PR NEWSWIRE
Innovent Presents At 43rd J.P. Morgan Healthcare Conference
16 Jan 2025 //
PR NEWSWIRE
Innovent & Ask Pharm Announce Approval of Limertinib For Cancer
16 Jan 2025 //
PR NEWSWIRE
Innovent`s Cancer Drug Receives Special Development Status
15 Jan 2025 //
PR NEWSWIRE
Innovent to Present at 43rd Annual J.P. Morgan Conference
05 Jan 2025 //
PR NEWSWIRE
Innovent’s Dovbleron Gets Second NDA Approval from NMPA
02 Jan 2025 //
PR NEWSWIRE
Innovent Enters into Agreement with Roche for Novel DLL3 ADC
02 Jan 2025 //
PR NEWSWIRE
Mankind Pharma inks pact with Innovent for immunotherapy drug
27 Dec 2024 //
PRESS RELEASE
Innovent Receives Approval for Dovbleron by China’s NMPA
20 Dec 2024 //
PR NEWSWIRE
Innovent & Lilly Expand Collaboration for Jaypirca
16 Dec 2024 //
PR NEWSWIRE
Innovent & Lilly Expand Collab for Jaypirca® Commercialization
15 Dec 2024 //
PR NEWSWIRE
Innovent: Anti-CLDN18.2 ADC Shows Progress in Pancreatic Cancer Trial
08 Dec 2024 //
PR NEWSWIRE
Innovent`s 1st-Time Inclusion of Sintbilo in China’s Reimburse list
27 Nov 2024 //
PR NEWSWIRE
Awaiting regulator verdict, Innovent posts latest psoriasis win
29 Oct 2024 //
FIERCE BIOTECH
Innovent Reports Phase 2 Results of Picankibart in Psoriasis
28 Oct 2024 //
PR NEWSWIRE
Innovent Ph 2 Of Picankibart In Ulcerative Colitis Met Endpoint
16 Oct 2024 //
PR NEWSWIRE
Innovent And Ask Pharm Collaborate On Limertinib For Lung Cancer
07 Oct 2024 //
PR NEWSWIRE
Innovent`s NDA For Picankibart Accepted By NMPA
26 Sep 2024 //
PR NEWSWIRE
Innovent links cytokine fusion protein to responses in colorectal cancer
18 Sep 2024 //
FIERCE BIOTECH
Innovent Presents Data In Combination With Bevacizumab For Colorectal Cancer
17 Sep 2024 //
PR NEWSWIRE
Innovent Presents Data In Ovarian, Breast, And Solid Tumors At ESMO 2024
17 Sep 2024 //
PR NEWSWIRE
Innovent`s Mazdutide Shows Superiority Over Dulaglutide In Diabetes Trial
11 Sep 2024 //
PR NEWSWIRE
Innovent Presents IBI363 Phase 1 Data At WCLC 2024
10 Sep 2024 //
PR NEWSWIRE
Innovent Biologics Highlights Lung Cancer Subgroup In Bispecific Study
10 Sep 2024 //
ENDPTS
